FKBP4 and breast carcinoma in situ: The authors examined by ELISA the presence of AAbs to five individual TAAs, PPIA, PRDX2, FKBP52, HSP-60, and MUC1, in sera from 60 breast carcinoma patients, 82 breast carcinoma in situ patients, and 93 healthy controls.